Fundación Real Madrid

GSK and the Real Madrid Foundation remind of the importance of prevention in the fight against malaria

NEWS | 24/04/2020

The population of the fifty or so countries in which the Foundation has socio-sports projects is exposed to this disease.
April 25 is World Malaria Day, a disease caused by parasites that are transmitted to humans through the bite of infected female Anopheles mosquitoes. Its prevention and treatment are of the utmost importance and, for this reason, the pharmaceutical company GSK and the Real Madrid Foundation are once again joining forces to remind us of the importance of the fight against this disease.

In 2018 alone, it has been estimated that there were 228 million cases of malaria in the world and that more than 400,000 people will die from this disease, 67% of whom will be children under the age of 5. GSK collaborates with the Real Madrid Foundation in social and sports projects for groups with respiratory conditions such as asthma, as well as in campaigns to promote health and healthy lifestyle habits with different educational activities to disseminate information among the more than 100,000 beneficiaries of the Real Madrid Foundation worldwide.


The Foundation and GSK have produced an informative video on how malaria affects children living in countries in Africa, a continent that bears a disproportionate share of the global burden of the disease. The video includes testimonies from beneficiaries in Senegal, Mauritania, Togo, Sierra Leone and Kenya, given that of the 103 countries in which the Real Madrid Foundation develops social and sports activities and projects, in 50 of them "malaria is a major social problem", according to the director of the International Area, Rosa Roncal.

Javier Gamo, Director of Biology at Global Health in GSK, comments that "more than half of the world's population is at risk of contracting malaria, but it is in areas where living conditions are most unfavourable that this disease has the greatest incidence. In Central America, South America, Southeast Asia and especially Africa is where most cases are concentrated, and what is worse, virtually all the deaths".

GSK has a research and development program that allows it to collaborate with the most prestigious universities and leading research centers to advance the treatment of this disease. In addition, it is investigating solutions for its prevention, such as the vaccine that is currently being used in a pilot vaccination program led by the World Health Organization in three African countries and for which GSK has donated 10 million doses of its candidate vaccine.